Ocrelizumab

Department of Health and Social Care written question – answered on 17th May 2019.

Alert me about debates like this

Photo of Heidi Allen Heidi Allen Acting Leader, Change UK

To ask the Secretary of State for Health and Social Care, what progress he has made on the (a) negotiations for NHS access to and (b) appraisal of Ocrelizumab as a treatment for primary progressive MS.

Photo of Seema Kennedy Seema Kennedy The Parliamentary Under-Secretary for Health and Social Care

The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent an effective use of NHS resources.

NICE is currently developing technology appraisal guidance on the use of ocrelizumab for treating primary progressive multiple sclerosis, with final guidance expected in June 2019. NHS England and Roche have now reached a commercial agreement and on 9 May NICE published final draft guidance which recommended ocrelizumab within its marketing authorisation, as an option for treating early primary progressive multiple sclerosis with imaging features characteristic of inflammatory activity in adults. Ocrelizumab will now be routinely available for eligible adults.

Does this answer the above question?

Yes3 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.